This is the first proof of principle for using adult cells reprogrammed to an embryonic-stem-cell-like state, combined with gene and cell therapy, for successful disease treatment in mice.
Whitehead Associate Member David Sabatini has been chosen by the W.M. Keck Foundation as one of this year’s grant recipients under the Distinguished Young Scholars in Medical Research program.